链霉菌次生代谢物化合物靶向的阿尔茨海默病相关蛋白:范围综述

IF 2.8 Q2 NEUROSCIENCES Journal of Alzheimer's disease reports Pub Date : 2023-12-16 DOI:10.3233/ADR-230065
Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman
{"title":"链霉菌次生代谢物化合物靶向的阿尔茨海默病相关蛋白:范围综述","authors":"Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman","doi":"10.3233/ADR-230065","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"21 3","pages":"1335 - 1350"},"PeriodicalIF":2.8000,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Alzheimer’s Disease-Related Proteins Targeted by Secondary Metabolite Compounds from Streptomyces: A Scoping Review\",\"authors\":\"Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman\",\"doi\":\"10.3233/ADR-230065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":\"21 3\",\"pages\":\"1335 - 1350\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/ADR-230065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/ADR-230065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:阿尔茨海默病(AD)是一种神经退行性疾病,其特征是认知能力快速、进行性下降,影响着全球 2600 万人。虽然免疫疗法是理想的治疗方法,但其临床安全性和有效性仍存在争议,因此治疗仍依赖对症药物。与此同时,链霉菌属因其有益于治疗神经退行性疾病的医药次生代谢产物而备受关注。目的:介绍链霉菌中对蛋白质有调节作用的次级代谢产物,并确定治疗 AD 的前瞻性靶蛋白。方法:从五个数据库中收集 2010 年至 2021 年间发表的研究文章,并确定了 83 篇相关研究文章。经过筛选,仅选取了 12 篇有关 AD 相关蛋白的研究文章进行进一步审查。通过检索相互作用基因/蛋白搜索工具(STRING)网络、PANTHER Go-Slim分类系统(PANTHER17.0)和京都基因和基因组百科全书(KEGG)映射器进行生物信息学分析。结果:从 12 篇入围文章中共鉴定出 20 个目标蛋白。鉴于淀粉样蛋白-β、BACE1、Nrf-2、Beclin-1和ATG5在诱发AD、减轻神经炎症和自噬中的作用,它们被确定为潜在的靶蛋白。此外,10 种来自链霉菌的化合物,包括雷帕霉素、alborixin、enterocin、bonnevillamides D 和 E、caniferolide A、anhydroexfoliamycin、rhizolutin、streptocyclinone A 和 B 被鉴定出对这些靶蛋白具有相当大的调节作用。结论:本综述重点介绍了几种可通过链霉菌化合物进行调控的潜在靶蛋白,以预防注意力缺失症的早期阶段和进展。建议进一步鉴定具有潜在抗 AD 特性的链霉菌化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Alzheimer’s Disease-Related Proteins Targeted by Secondary Metabolite Compounds from Streptomyces: A Scoping Review
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
期刊最新文献
Exploring shared molecular pathways and gene signatures in type 2 diabetes mellitus and Alzheimer's disease in a Pakistani cohort. P-tau217 and %p-tau217 exhibited superior diagnostic accuracy over other blood biomarkers in the initial assessment of individuals being diagnosed with mild cognitive impairment and Alzheimer's disease dementia. Characteristics of publicly available digital dementia risk screening tools: A scoping review. Insights into the role of extracellular-to-total body water ratio on neurocognitive decrements over time in Asians with type 2 diabetes. Multidimensional burden of caregivers of Alzheimer's disease and related dementia in China: A nationwide cross-sectional study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1